These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34606077)

  • 1. Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis.
    Schnitzer TJ; Berenbaum F; Conaghan PG; Dworkin RH; Gatti D; Yang R; Viktrup L; Davignon I; West CR; Verburg KM
    Rheumatol Ther; 2021 Dec; 8(4):1759-1774. PubMed ID: 34606077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
    Berenbaum F; Langford R; Perrot S; Miki K; Blanco FJ; Yamabe T; Isogawa N; Junor R; Carey W; Viktrup L; West CR; Brown MT; Verburg KM
    Eur J Pain; 2021 Aug; 25(7):1525-1539. PubMed ID: 33728717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study.
    Schnitzer TJ; Khan A; Bessette L; Davignon I; Brown MT; Pixton G; Prucka WR; Tive L; Viktrup L; West CR
    Semin Arthritis Rheum; 2020 Jun; 50(3):387-393. PubMed ID: 32252976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials.
    Berenbaum F; Schnitzer T; Kivitz A; Viktrup L; Johnston E; Yang R; Whalen E; Tive L; Semel D
    Int J Clin Pract; 2021 Dec; 75(12):e14975. PubMed ID: 34626502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies.
    Miki K; Ohta M; Abe M; Yoshimatsu H; Fujii K; Ebata N; West CR; Brown MT; Pixton G; Isogawa N
    Pain Ther; 2022 Sep; 11(3):827-844. PubMed ID: 35538185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
    Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.
    Neogi T; Hunter DJ; Churchill M; Shirinsky I; White A; Guermazi A; Omata M; Fountaine RJ; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Res Ther; 2022 Mar; 24(1):78. PubMed ID: 35351194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.
    Spierings ELH; Fidelholtz J; Wolfram G; Smith MD; Brown MT; West CR
    Pain; 2013 Sep; 154(9):1603-1612. PubMed ID: 23707270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab.
    Hunter DJ; Schnitzer TJ; Hall J; Semel D; Davignon I; Cappelleri JC; Bushmakin AG; Abraham L
    Osteoarthr Cartil Open; 2022 Sep; 4(3):100294. PubMed ID: 36474952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical Trials.
    Colloca L; Dworkin RH; Farrar JT; Tive L; Yang J; Viktrup L; Dasic G; West CR; Whalen E; Brown MT; Gilbert SA; Verburg KM
    Clin Pharmacol Ther; 2023 Apr; 113(4):878-886. PubMed ID: 36621827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tanezumab for the treatment of pain from osteoarthritis of the knee.
    Lane NE; Schnitzer TJ; Birbara CA; Mokhtarani M; Shelton DL; Smith MD; Brown MT
    N Engl J Med; 2010 Oct; 363(16):1521-31. PubMed ID: 20942668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee.
    Conaghan PG; Dworkin RH; Schnitzer TJ; Berenbaum F; Bushmakin AG; Cappelleri JC; Viktrup L; Abraham L
    J Rheumatol; 2022 Jun; 49(6):615-621. PubMed ID: 35232805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial.
    Tambiah JRS; Kennedy S; Swearingen CJ; Simsek I; Yazici Y; Farr J; Conaghan PG
    Rheumatol Ther; 2021 Jun; 8(2):973-985. PubMed ID: 34101138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip.
    Tive L; Bello AE; Radin D; Schnitzer TJ; Nguyen H; Brown MT; West CR
    J Pain Res; 2019; 12():975-995. PubMed ID: 30936738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.
    Bruyère O; Reginster JY; Bellamy N; Chapurlat R; Richette P; Cooper C;
    Rheumatology (Oxford); 2014 Aug; 53(8):1457-64. PubMed ID: 24667161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
    Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis.
    Birbara C; Dabezies EJ; Burr AM; Fountaine RJ; Smith MD; Brown MT; West CR; Arends RH; Verburg KM
    J Pain Res; 2018; 11():151-164. PubMed ID: 29386912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient acceptable symptom state and OMERACT-OARSI set of responder criteria in joint replacement. Identification of cut-off values.
    Escobar A; Gonzalez M; Quintana JM; Vrotsou K; Bilbao A; Herrera-Espiñeira C; Garcia-Perez L; Aizpuru F; Sarasqueta C
    Osteoarthritis Cartilage; 2012 Feb; 20(2):87-92. PubMed ID: 22155074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.